• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Personalized Medicine Partnering Terms and Agreements 2014 Product Image

Personalized Medicine Partnering Terms and Agreements 2014

  • ID: 2300222
  • November 2014
  • Region: Global
  • 1289 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Biogen Idec
  • Daiichi Sankyo
  • Johnson & Johnson
  • Novartis
  • Roche
  • MORE

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals and incorporates Biomarkers, Companion Diagnostics and Pharmacogenomics. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest personalized medicine agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all personalized medicine partnering deals announced since 2009 including financial terms where available including over 1,000 links to online deal records of actual personalized medicine partnering deals as disclosed by the deal parties. In addition, READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Biogen Idec
  • Daiichi Sankyo
  • Johnson & Johnson
  • Novartis
  • Roche
  • MORE

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in personalized medicine dealmaking

2.1. Introduction
2.2. Personalized medicine partnering over the years
2.2.1 Biomarker partnering over the years
2.2.2 Companion diagnostic partnering over the years
2.2.3 Pharmacogenomics partnering over the years
2.3. Big pharma personalized medicine dealmaking activity
2.3.1 Big pharma biomarker, companion diagnostic and pharmacogenomics dealmaking activity
2.4. Most active in personalized medicine
2.5. Personalized medicine partnering by deal type
2.5.1 Biomarker partnering by deal type
2.5.2 Companion diagnostic partnering by deal type
2.5.3 Pharmacogenomics partnering by deal type
2.6. Personalized medicine partnering by disease type
2.6.1 Biomarker partnering by disease type
2.6.2 Companion diagnostic partnering by disease type
2.6.3 Pharmacogenomics partnering by disease type
2.7 Average deal terms for personalized medicine
2.7.1 Personalized medicine headline values by year
2.7.2 Personalized medicine upfront payments by year
2.7.3 Personalized medicine milestone payments by year
2.7.4 Personalized medicine royalty rates by year

Chapter 3 - Leading biomarker deals

3.1. Introduction
3.2. Top biomarker deals by value

Chapter 4 - Leading companion diagnostic deals

4.1. Introduction
4.2. Top companion diagnostic deals by value

Chapter 5 - Leading pharmacogenomics deals

5.1. Introduction
5.2. Top pharmacogenomics deals by value

Chapter 6 - Big pharma personalized medicine deals

6.1. Introduction
6.2. How to use big pharma personalized medicine partnering deals
6.3. Big pharma personalized medicine partnering company profiles
Abbott
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
Daiichi Sankyo
Eisai
Eli Lilly
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva
UCB

Chapter 7 - Biomarker contracts dealmaking directory

7.1. Introduction
7.2. Biomarker partnering deals with a contract available by company A-Z
7.3. Biomarker partnering deals with a contract available by by deal type
7.4. Biomarker partnering deals with a contract available by therapy type

Chapter 8 - Companion diagnostic contracts dealmaking directory

8.1. Introduction
8.2. Companion diagnostic partnering deals with a contract available by company A-Z
8.3. Companion diagnostic partnering deals with a contract available by deal type
8.4. Companion diagnostic partnering deals with a contract available by therapy area

Chapter 9 - Pharmacogenomics contracts dealmaking directory

9.1. Introduction
9.2. By Company A-Z
9.3. By deal type

Chapter 10 - Personalized medicine dealmaking directory by specific technology type

Personalized medicine
Pharmacogenomics
Biomarkers
Companion Diagnostics

Chapter 11 - Personalized medicine partnering resource center

11.1. Online personalized medicine partnering
11.2. Personalized medicine partnering events
11.3. Further reading on personalized medicine dealmaking

Note: Product cover images may vary from those shown

Abbott
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
Daiichi Sankyo
Eisai
Eli Lilly
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva
UCB

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos